TVGN | tickerfilter.com

Fundamental analysis

31%

Profitability 35%

Dept financing 43%

Liquidity 10%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-14.04%

1 Month

51.28%

3 Months

2,074.20%

6 Months

953.74%

1 Year

542.57%

2 Year

549.06%

Key data

Stock price

$6.49

P/E Ratio

0.00

DAY RANGE

$6.47 - $7.00

EPS

-$0.06

52 WEEK RANGE

$0.14 - $10.76

52 WEEK CHANGE

$530.10

MARKET CAP

154.472 M

YIELD

N/A

SHARES OUTSTANDING

198.690 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-29-2025

BETA

-0.83

PUBLIC FLOAT

AVERAGE 10 VOLUME

$27,074

AVERAGE 30 VOLUME

$24,768

Company detail

CEO: Ryan Saadi
Region: US
Website: tevogen.com
Employees: 3
IPO year: 2022

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company was founded in 2020 and is based in Warren, New Jersey.

TVGN - Tevogen Bio Holdings Inc.